Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer? Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 4, 2006, Pages 178-179

  Seidman, Andrew D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant; Breast cancer; HER2 positive; Trastuzumab therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SHORT SURVEY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 33645711515     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0460     Document Type: Short Survey

References (5)

1. Romond EH et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684
2. Slamon D et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab and with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer: BCIRG 006 study [abstract #1]. Breast Can Res Treat 94: S5
3. Seidman AD et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221
4. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 365: 1687-1717
5. [No authors listed] (2005) Helping the informed patient decide [editorial]. Lancet 365: 2064